BioCentury
ARTICLE | Product Development

O’Day’s expansive task at Gilead

How incoming Gilead CEO O’Day could make the biotech’s move into new therapeutic areas a success

December 15, 2018 4:43 AM UTC

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of virology.

The first read of his success may not come until 2021, after Gilead launches its first autoimmune drug. ...

BCIQ Company Profiles

Gilead Sciences Inc.

Roche